Darifenacin - CAS 133099-04-4
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. Darifenacin hydrobromide has 9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4. Darifenacin is used clinically to treat urinary incontinence and overactive bladder syndrome.
Publictions citing BOC Sciences Products
  • >> More
UK-88525; UK 88525; UK88525
1. Synthesis and Properties of Molecular Imprints of Darifenacin: The Potential of Molecular Imprinting for Bioanalysis
R. E Verm*, R. J. Goody. Chromatographia Vol. 50, No. 7/8, October 1999
A molecularly imprinted polymer has been developed which subsequently demonstrated an ability to selectively retain darifenacin (UK-88,525-S) from aqueous acetonitrile when used as a stationary phase in HPLC columns and as a packing in solid-phase extraction cartridges. The imprinted polymer is applicable to a wide range of analytical methods including extraction from plasma, purification ofradiolabelled UK-88,525, chiral separations and separation of metabolites and structural analogues. The polymer is able to extract darifenacin directly from a protein-precipitated human plasma/acetonitrile (1:1 v/v) mixture with 100 % recovery. The imprinted polymer can also effect a repurification of 14C-labelled darifenacin.
2. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study
Simon Hill, Vik Khullar, Jean-Jacques Wyndaele, Karine Lheritier. Int Urogynecol J (2006) 17: 239–247
Darifenacin is a novel agent that shows high selectivity for human muscarinic M3 receptors in vitro. Preliminary studies have confirmed that darifenacin has aclinical profile consistentwith its M3 selective andM1- and M2-sparing properties as it conveys pronounced urodynamic efficacy with no evidence of cognitive impairment or cardiac effects. The aim of the present study was to further evaluate the efficacy, tolerability, and safety of varying doses of darifenacin in patients with OAB.
3. Time-to-effect with darifenacin in overactive bladder: a pooled analysis
Vik Khullar & Jenelle Foote & Yodit Seifu & Mathias Egermark. Int Urogynecol J (2011) 22:1573–1580
Clinical studies with darifenacin, a highly selective M3-receptor antagonist, have demonstrated its efficacy and safety in patients with OAB during 12 weeks of treatment and in long-term use. Pooled efficacy data from three phase III studies have been published for week 12, whereas this analysis specifically evaluates efficacy data for the earlier study visits of weeks 2 and 6. In addition, a retrospective analysis was performed to examine data from the earliest available timepoints of these studies to determine when the drug effect first becomes apparent for the two available doses of darifenacin (7.5 and 15 mg). The improvements observed at week 2 were then calculated as percentages of the final treatment effect observed at the end of the study to describe the progress of treatment effect over time.
4. Darifenacin
A Viewpoint by Francois Haab. Drugs Aging 2004; 21 (13): 893-894
As predicted by its M3 selectivity, darifenacin appears to be well tolerated, with cardiovascular and nervous system event rates similar to placebo; this is also the case for the incidence of blurred vision. Dry mouth still occurs with darifenacin, although at a lower incidence than with oxybutynin. Notably, the drug has no cognitive function effects in elderly patients; these data appear to be the first of their kind amongst the antimuscarinics. This safety profile, together with strong clinical efficacy, positions darifenacin as a valuable treatment for the symptoms of overactive bladder. Whether this profile translates into significant clinical advantages will hopefully become clear following the longer-term use of darifenacin in general practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mAChR Products

CAS 409351-28-6 VU0152100

(CAS: 409351-28-6)

VU0152100 is a selective and positive allosteric modulators of M4 receptor. It has shown a potent positive allosteric modulators that increase the response of t...

CAS 171722-81-9 YM-46303

(CAS: 171722-81-9)

YM-46303 is an mAChR antagonist which had a binding affinity of 0.39 nM to M3-receptors. YM-46303 exhibits the highest affinities for M1 and M3 receptors. YM-46...

CAS 1227923-29-6 MK-7622

(CAS: 1227923-29-6)

MK-7622 is a cholinesterase inhibitor under evaluation for the treatment of Alzheimer's disease. No studies have been published on this compound in the peer-rev...

CAS 149-64-4 Scopolamine butylbromide

Scopolamine butylbromide
(CAS: 149-64-4)

Scopolamine is an anti-muscarinic and cholinolytic alkaloid that inhibits parasympathetic-cholinergic system. The central effects include hallucinations, disori...

CAS 54-30-8 Camylofine dihydrochloride

Camylofine dihydrochloride
(CAS: 54-30-8)

Camylofine dihydrochloride is an antimuscarinic used as a smooth muscle relaxant.

CAS 133099-04-4 Darifenacin

(CAS: 133099-04-4)

Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsi...

CAS 84504-69-8 Irsogladine maleate

Irsogladine maleate
(CAS: 84504-69-8)

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. It inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout...

CAS 5908-99-6 Atropine sulfate salt monohydrate

Atropine sulfate salt monohydrate
(CAS: 5908-99-6)

Atropine is a competitive muscarinic acetylcholine receptor antagonist with an IC50 of 2.5 nM.

CAS 3717-88-2 Flavoxate hydrochloride

Flavoxate hydrochloride
(CAS: 3717-88-2)

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by an...

CAS 514-65-8 Biperiden

(CAS: 514-65-8)

Biperiden is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. It is used for the adjunctive treatment of all forms of Park...

CI 969
(CAS: 113590-49-1)

This active molecular is a muscarinic agonist agent.

CAS 80-50-2 Anisotropine methyl bromide

Anisotropine methyl bromide
(CAS: 80-50-2)

Anisotropine methylbromide is a muscarinic antagonist and antispasmodic. It was an adjunct in the treatment of peptic ulcer and promoted as being more specific ...

CAS 54-71-7 Pilocarpine Hydrochloride

Pilocarpine Hydrochloride
(CAS: 54-71-7)

Pilocarpine HCl is a nonselective muscarinic acetylcholine receptor agonist used to produce an experimental model of epilepsy.

CAS 124937-51-5 (R)-(+)-Tolterodine

(CAS: 124937-51-5)

A muscarinic receptor antagonist. Used in the treatment of urinary incontinence.

CAS 113-69-9 Benzquinamide Hydrochloride

Benzquinamide Hydrochloride
(CAS: 113-69-9)

Benzquinamide hydrochloride is an antiemetic compound with antihistaminic, anticholinergic and sedative properties. The mechanism of action is not quite sure an...

CAS 70704-03-9 Vinconate

(CAS: 70704-03-9)

Vinconate, a vinca alkaloid derivative, can stimulate the muscariic acetylcholine receptor. Vinconate prevents ischemic neuronal damage by direct action on the ...

CAS 155-41-9 Methscopolamine

(CAS: 155-41-9)

Methscopolamine is a muscarinic acetylcholine receptor blocker.

CAS 57381-26-7 Irsogladine

(CAS: 57381-26-7)

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reductio...

Desfesoterodine fumarate
(CAS: 380636-50-0)

Desfesoterodine is the active metabolite of fesoterodine as its isobutyrate ester.

CAS 114-49-8 Scopolamine HBr

Scopolamine HBr
(CAS: 114-49-8)

Scopolamine HBr is a competitive muscarinic acetylcholine receptor with an IC50 of 55.3 nM.

Chemical Structure

CAS 133099-04-4 Darifenacin

Quick Inquiry

Verification code

Featured Items